Target Information
| Target General Information | Top | |||||
|---|---|---|---|---|---|---|
| Target ID |
T02246
(Former ID: TTDI01910)
|
|||||
| Target Name |
Iron (Fe)
|
|||||
| Gene Name |
NO-GeName
|
|||||
| Target Type |
Successful target
|
[1] | ||||
| Disease | [+] 3 Target-related Diseases | + | ||||
| 1 | Low bone mass disorder [ICD-11: FB83] | |||||
| 2 | Mineral absorption/transport disorder [ICD-11: 5C64] | |||||
| 3 | Thalassaemia [ICD-11: 3A50] | |||||
| UniProt ID | ||||||
| Drugs and Modes of Action | Top | |||||
|---|---|---|---|---|---|---|
| Approved Drug(s) | [+] 4 Approved Drugs | + | ||||
| 1 | Deferiprone | Drug Info | Approved | Thalassemia | [1], [2] | |
| 2 | Deferoxamine Mesylate | Drug Info | Approved | Acute iron or aluminum toxicity | [3] | |
| 3 | Etidronate Disodium | Drug Info | Approved | Osteoporosis | [3] | |
| 4 | Exjade | Drug Info | Approved | Iron overload disease | [4] | |
| Clinical Trial Drug(s) | [+] 4 Clinical Trial Drugs | + | ||||
| 1 | Soluble ferric pyrophosphate | Drug Info | Phase 3 | Iron-deficiency anemia | [5] | |
| 2 | SPD602 | Drug Info | Phase 2 | Anemia | [6] | |
| 3 | DpC | Drug Info | Phase 1 | Solid tumour/cancer | [7] | |
| 4 | Monohydroxyethylrutoside | Drug Info | Phase 1 | Cardiovascular disease | [8] | |
| Mode of Action | [+] 2 Modes of Action | + | ||||
| Modulator | [+] 7 Modulator drugs | + | ||||
| 1 | Deferiprone | Drug Info | [1] | |||
| 2 | Deferoxamine Mesylate | Drug Info | [9] | |||
| 3 | Etidronate Disodium | Drug Info | [9] | |||
| 4 | Exjade | Drug Info | [10] | |||
| 5 | Soluble ferric pyrophosphate | Drug Info | [11] | |||
| 6 | SPD602 | Drug Info | [12] | |||
| 7 | Monohydroxyethylrutoside | Drug Info | [14] | |||
| Chelator | [+] 1 Chelator drugs | + | ||||
| 1 | DpC | Drug Info | [13] | |||
| Drug Property Profile of Target | Top | |
|---|---|---|
| (1) Molecular Weight (mw) based Drug Clustering | (2) Octanol/Water Partition Coefficient (xlogp) based Drug Clustering | |
|
|
||
| (3) Hydrogen Bond Donor Count (hbonddonor) based Drug Clustering | (4) Hydrogen Bond Acceptor Count (hbondacc) based Drug Clustering | |
|
|
||
| (5) Rotatable Bond Count (rotbonds) based Drug Clustering | (6) Topological Polar Surface Area (polararea) based Drug Clustering | |
|
|
||
| "RO5" indicates the cutoff set by lipinski's rule of five; "D123AB" colored in GREEN denotes the no violation of any cutoff in lipinski's rule of five; "D123AB" colored in PURPLE refers to the violation of only one cutoff in lipinski's rule of five; "D123AB" colored in BLACK represents the violation of more than one cutoffs in lipinski's rule of five | ||
| References | Top | |||||
|---|---|---|---|---|---|---|
| REF 1 | 2011 FDA drug approvals. Nat Rev Drug Discov. 2012 Feb 1;11(2):91-4. | |||||
| REF 2 | URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 7456). | |||||
| REF 3 | Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2015 | |||||
| REF 4 | 2005 approvals: Safety first. Nature Reviews Drug Discovery 5, 92-93 (February 2006). | |||||
| REF 5 | Clinical pipeline report, company report or official report of Rockwell Medical Inc. | |||||
| REF 6 | ClinicalTrials.gov (NCT01671111) Study for Transfusionally Iron Overloaded Children, Adolescents and Adults Using FBS0701 (SSP-004184). U.S. National Institutes of Health. | |||||
| REF 7 | ClinicalTrials.gov (NCT02688101) Dose-finding and Pharmacokinetic Study of DpC, Administered Orally to Patients With Advanced Solid Tumors. U.S. National Institutes of Health. | |||||
| REF 8 | A phase I study of monohydroxyethylrutoside in healthy volunteers. Cancer Chemother Pharmacol. 2006 May;57(5):678-84. | |||||
| REF 9 | Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. | |||||
| REF 10 | Deferasirox : a review of its use in the management of transfusional chronic iron overload. Drugs. 2007;67(15):2211-30. | |||||
| REF 11 | A micronised, dispersible ferric pyrophosphate with high relative bioavailability in man. Br J Nutr. 2004 Jan;91(1):107-12. | |||||
| REF 12 | ClinicalTrials.gov (NCT01604941) Pharmacokinetics of SSP-004184 in the Treatment of Chronic Iron Overload Requiring Chelation Therapy. U.S. National Institutes of Health. | |||||
| REF 13 | Anticancer Thiosemicarbazones: Chemical Properties, Interaction with Iron Metabolism, and Resistance Development. Antioxid Redox Signal. 2019 Mar 10;30(8):1062-1082. | |||||
| REF 14 | Monohydroxyethylrutoside, a dose-dependent cardioprotective agent, does not affect the antitumor activity of doxorubicin. Clin Cancer Res. 1997 Oct;3(10):1747-54. | |||||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.